LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules

Executive Summary

• LIR Life Sciences completed the design phase for an ex‑vivo porcine skin study to assess transdermal delivery of macromolecular therapeutics (5 kDa – ~150 kDa).
• The study will compare formulations containing novel transdermal agents against matched controls, using confocal microscopy and quantitative fluorescence measurements.
• Execution of the study is slated for Q1 2026, with results intended to guide future needle‑free delivery strategies for large therapeutic molecules.

Key Details

• Study design finalized with scientific partners; utilizes full‑thickness porcine skin as a human‑relevant model.
• Target analytes span from 5 kDa peptides up to antibody‑scale (~150 kDa) therapeutics.
• Evaluation methods: confocal microscopy for penetration depth and distribution; quantitative fluorescence at predefined time points.
• Planned timeline: design completed → study execution in Q1 2026 → results to inform compatibility of larger molecules with skin‑applied, needle‑free delivery.
• CEO Edward Mills emphasized the disciplined methodology aimed at de‑risking the science and advancing a practical needle‑free approach.

Notable Quotes

“Our focus in designing this study was to de‑risk the science with a disciplined methodology that uses a human relevant skin model and rigorous quantitative analysis. We believe there is real potential here, and are excited to implement the study so we can determine whether the novel transdermal agents deliver the level of penetration we expect…” – Edward Mills, CEO, LIR Life Sciences Corp.